Inappropriate use of oral ciprofloxacin.
暂无分享,去创建一个
[1] L. Piddock,et al. Quinolone resistance in salmonella: clinical experience , 1990, The Lancet.
[2] L. Shulman,et al. Second trimester maternal serum human chorionic gonadotropin and unconjugated oestriol levels in blacks and whites , 1990, The Lancet.
[3] P. Huovinen,et al. Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. , 1990, The Journal of infectious diseases.
[4] E. McGoodwin,et al. Anaphylactoid reactions reported after treatment with ciprofloxacin. , 1989, Annals of internal medicine.
[5] G. Reaven,et al. Hypertension as a disease of carbohydrate and lipoprotein metabolism. , 1989, The American journal of medicine.
[6] R. Lang,et al. Ciprofloxacin treatment of malignant external otitis. , 1989, The American journal of medicine.
[7] H. Neu,et al. Resistance to ciprofloxacin appearing during therapy. , 1989, The American journal of medicine.
[8] R. Smego,et al. Eosinophilic meningitis associated with ciprofloxacin. , 1989, The American journal of medicine.
[9] P. Pizzo. Considerations for the prevention of infectious complications in patients with cancer. , 1989, Reviews of infectious diseases.
[10] B. Cooper,et al. Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia. , 1989, The American journal of medicine.
[11] A. Fenves,et al. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature. , 1989, Clinical nephrology.
[12] K. Naber. Use of quinolones in urinary tract infections and prostatitis. , 1989, Reviews of infectious diseases.
[13] K. Teisala,et al. A comparison of ciprofloxacin with doxycycline plus metronidazole in the treatment of acute pelvic inflammatory disease. , 1989, Scandinavian journal of infectious diseases. Supplementum.
[14] Sanders We. Efficacy, Safety, and Potential Economic Benefits of Oral Ciprofloxacin in the Treatment of Infections , 1988 .
[15] I. Phillips,et al. 3 – In vitro Properties of the Quinolones , 1988 .
[16] J. Thys. Quinolones in the treatment of bronchopulmonary infections. , 1988, Reviews of infectious diseases.
[17] C. Nord. Effect of new quinolones on the human gastrointestinal microflora. , 1988, Reviews of infectious diseases.
[18] J. Lähdevirta,et al. TREATMENT OF CHRONIC SALMONELLA CARRIERS WITH CIPROFLOXACIN , 1987, The Lancet.
[19] C. Sanders,et al. Efficacy of ciprofloxacin in the treatment of nasopharyngeal carriers of Neisseria meningitidis. , 1987, The Journal of infectious diseases.
[20] A. Sivonen,et al. Effect of ciprofloxacin on carrier rate of Neisseria meningitidis in army recruits in Finland , 1987, Antimicrobial Agents and Chemotherapy.
[21] R. Spencer,et al. Comparative in-vitro activity of five fluoroquinolones against mycobacteria. , 1987, The Journal of antimicrobial chemotherapy.
[22] T. Tupasi,et al. Social, behavioral, and practical factors affecting antibiotic use worldwide: report of Task Force 4. , 1987, Reviews of infectious diseases.
[23] Neu Hc. Ciprofloxacin: an overview and prospective appraisal. , 1987 .
[24] L. Parish,et al. Systemic treatment of cutaneous infections. A comparative study of ciprofloxacin and cefotaxime. , 1987, The American journal of medicine.
[25] H. Neu,et al. Ciprofloxacin therapy in cystic fibrosis. , 1987, The American journal of medicine.
[26] R. Greenblatt,et al. Treatment of chancroid with ciprofloxacin. A prospective, randomized clinical trial. , 1987, The American journal of medicine.
[27] G. Pankey,et al. Ciprofloxacin in the treatment of bacterial skin infections , 1987 .
[28] W. Franck,et al. Vitamin D toxicity complicating the treatment of senile, postmenopausal, and glucocorticoid-induced osteoporosis. Four case reports and a critical commentary on the use of vitamin D in these disorders. , 1987, The American journal of medicine.
[29] T. Rubio,et al. Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients. , 1986, The Journal of antimicrobial chemotherapy.
[30] R. Garibaldi,et al. Epidemiology of community-acquired respiratory tract infections in adults , 1985, The American Journal of Medicine.
[31] H. Neu,et al. Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks , 1985, Journal of clinical microbiology.
[32] C. Kunin. The responsibility of the infectious disease community for the optimal use of antimicrobial agents. , 1985, The Journal of infectious diseases.
[33] R. Prabhala,et al. In vitro susceptibility of anaerobic bacteria to ciprofloxacin (Bay o 9867) , 1984, Antimicrobial Agents and Chemotherapy.
[34] C. Kunin. Antibiotic resistance--a world health problem we cannot ignore. , 1983, Annals of internal medicine.
[35] B. Rosner,et al. Use of antimicrobial drugs in general hospitals: patterns of prophylaxis. , 1979, The New England journal of medicine.
[36] D. Maki,et al. A study of antimicrobial misuse in a university hospital. , 1978, The American journal of the medical sciences.
[37] P. Stolley,et al. This is medical progress? Trends and consequences of antibiotic use in the United States. , 1974, JAMA.
[38] L. Lasagna,et al. Drug prescribing and use in an American community. , 1972, Annals of internal medicine.
[39] W. Scheckler,et al. Antibiotic usage in seven community hospitals. , 1970, JAMA.